ClinicalTrials.gg
RecruitingNCT07579442Updated Oct 6, 2026

Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)

An interventional study of Narrative Medicine (NM) Workshop Series in Anorexia Nervosa, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 16 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
16 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Planned enrollment
129th of 143
10 · median 40
Started
2026
with 8 others
No phase
94 of 174
24 open now
Primary completion
2027-07
later than 25 of 44 live
Registered
169th of 174
by date
Lead sponsor
6 of 174
University of California, San Francisco

Among the 174 studies in Anorexia Nervosa with a site in United States, this one is the 129th largest by planned enrollment of the 143 interventional ones that give a count, is one of 9 that started in 2026, is one of 94 with no phase, reaches primary completion later than 25 of the 44 other live ones, and was the 169th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 174 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 16 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa.

The main questions it aims to answer are:

  • Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa?
  • Does engaging in creative writing and group discussion promote resilience and emotional processing in this population?

Participants will be 16-25 years old, medically stable for outpatient eating disorder therapy, and actively engaged in treatment. Those with active suicidal ideation, recent non-suicidal self-injury, or a co-occurring personality disorder will not be eligible.

Participants will:

  • Attend six weekly workshops focused on themes such as self-definition, kindness, resilience, and possibility
  • Engage in close reading of visual or written texts
  • Complete creative writing exercises in response to prompts
  • Participate in group discussions and sharing

An optional capstone reading event will provide a supportive space for participants to share their work with peers, loved ones, and providers, fostering connection and community.

This study aims to explore the role of narrative medicine in eating disorder treatment and assess its potential benefits for psychological well-being and self-expression.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

04

Who can participate

Ages eligible
16 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16-25 years old
  • have a diagnosis of AN (confirmed by the UCSF Eating Disorders Program clinical team),
  • currently engaged in outpatient eating disorder treatment, ensuring medical stability and capacity for a group-based intervention
  • English fluency to engage in reflective writing and discussions
  • Cognitive ability to meaningfully participate in narrative-based exercises

Exclusion criteria

Exclusion Criteria:

  • Currently medically unstable or require inpatient hospitalization
  • History of psychosis, schizophrenia spectrum disorder, bipolar disorder, or personality disorder
  • Severe neurocognitive impairment that would prevent engagement with the intervention
  • Active suicidal ideation or non-suicidal self-injury within the past two months
  • Insufficient English proficiency to participate in group discussions and writing exercises
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Narrative Medicine (NM) Workshop Series

    Participants in this study will take part in a six-week Narrative Medicine (NM) curriculum designed to enhance self-expression, reflection, and resilience in individuals with anorexia nervosa. Workshops will be conducted weekly on Zoom and will include: * Close reading of visual or written texts related to themes such as self-definition, resilience, kindness, and possibility * Creative writing exercises in response to structured prompts * Group discussions and sharing to foster community, connection, and self-expression

    Behavioral: Narrative Medicine (NM) Workshop Series

Interventions

  • BehavioralNarrative Medicine (NM) Workshop Series

    The Narrative Medicine (NM) Workshop Series is a structured six-week behavioral intervention designed to enhance self-expression, reflection, and resilience in adolescents and young adults recovering from eating disorders. This intervention differs from traditional psychotherapeutic or psychoeducational approaches by integrating literary analysis, creative writing, and guided discussion as therapeutic tools. Each one-hour weekly workshop includes: * Close reading of visual or written texts related to themes such as self-definition, resilience, kindness, and possibility * Creative writing exercises in response to structured prompts that encourage self-reflection and personal storytelling * Facilitated group discussions to foster connection, self-expression, and emotional processing in a supportive environment

06

What researchers measure

Primary outcomes

  1. Number of participants in each session

    Feasibility will be measured by participant retention in intervention.

    Time frame: Immediately post-intervention (Week 6)

  2. Satisfaction with intervention components using 5-point Likert scales and semi-structured individual interviews

    Acceptability will be measured by questionnaire including 5-point Likert scales and semi-structured individual interviews assessing content relevance, writing prompts, group discussions, and facilitation. Scale title: Intervention Satisfaction Questionnaire (ISQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Higher scores indicate greater satisfaction with the intervention (better outcome).

    Time frame: Immediately post-intervention (Week 6)

Secondary outcomes

  1. Illness-Identity Centrality

    Assessed using the Illness Identity Questionnaire, which evaluates self-concept clarity and personal identity coherence. Scale title: Illness Identity Questionnaire (IIQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Subscale scores reflect distinct illness identity states; higher scores indicate greater endorsement of that identity orientation

    Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)

  2. Social Connectedness

    Measured using the Social Connectedness Scale (SCS), which assesses perceived closeness to others and sense of belonging. Scale title: Social Connectedness Scale (SCS) Minimum value: 1 (Strongly Disagree) Maximum value: 6 (Strongly Agree) Interpretation: Higher scores indicate greater feelings of social connectedness and belonging (better outcome).

    Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)

  3. Depression Symptoms

    Measured using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms. Scale title: Patient Health Questionnaire-9 (PHQ-9) Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of depressive symptoms (worse outcome).

    Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)

  4. Anxiety Symptoms

    Measured using the Generalized Anxiety Disorder-7 (GAD-7) for anxiety. Scale title: Generalized Anxiety Disorder 7-item (GAD-7) Scale Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of anxiety symptoms (worse outcome).

    Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)

  5. Eating Disorder Severity

    Measured using the Eating Disorder Examination Questionnaire (EDE-Q), which captures cognitive and behavioral symptoms of AN, and percent of expected body weight (EBW) at follow-up. Scale title: Eating Disorder Examination Questionnaire (EDE-Q) Minimum value: 0 (No days / Not at all) Maximum value: 6 (Every day / Extremely) Interpretation: Higher scores indicate greater severity of eating disorder psychopathology (worse outcome).

    Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Knio L, Sridhar H. Phenomenology of Identity: Narrative Medicine Curricula in the Care of Eating Disorders. J Med Humanit. 2025 Dec;46(4):673-696. doi: 10.1007/s10912-025-09929-6. Epub 2025 Jan 27. PubMed 39869237 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 8 months is below that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 12, 2026
StartActual
Oct 2, 2026was Aug 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
UCSF Nancy Friend Pritzker Psychiatry Building is now Recruiting
Oct 6, 2026
Start date
Aug 15, 2026→Oct 2, 2026 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    UCSF Nancy Friend Pritzker Psychiatry Building is now Recruiting
    Start date Aug 15, 2026→Oct 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07579442
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Oct 2, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Anoushka A Sinha, MD, MS
Contact
anoushka.sinha@ucsf.edu
628-286-6116
Anoushka Sinha, MD, MS
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion